Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Status:
Completed
Trial end date:
2014-05-29
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of vaccine therapy when given together with
sargramostim in treating patients with malignant glioma. Vaccines made from survivin peptide
may help the body build an effective immune response to kill tumor cells. Colony-stimulating
factors, such as sargramostim, may increase the number of white blood cells and platelets
found in bone marrow or peripheral blood. Giving vaccine therapy and sargramostim may be a
better treatment for malignant glioma.